%PDF-1.4
%
87 0 obj
<>
endobj
84 0 obj
<>
endobj
434 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-26T19:22:20Z
2024-03-29T08:51:09-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T08:51:09-07:00
application/pdf
Heather
201237.june
uuid:5648347d-1dd2-11b2-0a00-1c0a27bd7700
uuid:5648347f-1dd2-11b2-0a00-900000000000
endstream
endobj
70 0 obj
<>
endobj
72 0 obj
<>
endobj
71 0 obj
<>
endobj
73 0 obj
<>
endobj
74 0 obj
<>
endobj
58 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
61 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
441 0 obj
[446 0 R]
endobj
442 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 72 714.5293 Tm
(J Rheumatol 1998;25:1895-9.)Tj
-2.25 -1.25 Td
[(224.)-500 (Pincus )18 (T)74 (, Marcum SB, Callahan LF)80 (. Long term drug therapy for RA)]TJ
2.25 -1.25 Td
(in 7 rheumatology private practices: 2nd line drugs and prednisone.)Tj
0 -1.25 TD
(J Rheumatol 1992;19:1885-94.)Tj
-2.25 -1.25 Td
[(225.)-500 (W)80 (olfe F)80 (. 50 years of antirheumatic therapy: the prognosis of)]TJ
2.25 -1.25 Td
(rheumatoid arthritis. J Rheumatol 1990;17 Suppl 22:24-32.)Tj
-2.25 -1.25 Td
[(226.)-500 (W)40 (ilske KR, Healey LA. Remodelling the pyramid: a concept whose)]TJ
2.25 -1.25 Td
(time has come. J Rheumatol 1989;16:565-7.)Tj
-2.25 -1.25 Td
[(227.)-500 (W)40 (ilske KR, Healey LA. Challenging the therapeutic pyramid: a new)]TJ
2.25 -1.25 Td
(look at treatment strategies for rheumatoid arthritis. J Rheumatol)Tj
T*
(1990;17 Suppl 25:4-7.)Tj
-2.25 -1.25 Td
[(228.)-500 (McCarty DJ. Suppress rheumatoid inflammation early and leave the)]TJ
2.25 -1.25 Td
[(pyramid to the Egyptians. J Rheumatol 1990;17:1)37 (1)37 (15-8.)]TJ
-2.25 -1.25 Td
[(229.)-500 (Fries JF)80 (. Re-evaluating the therapeutic approach to rheumatoid)]TJ
2.25 -1.25 Td
[(arthritis: the \223saw tooth\224 strategy)65 (. J Rheumatol 1990;17 Suppl)]TJ
0 Tw T*
(22:12-5.)Tj
0.0249 Tw -2.25 -1.25 Td
[(230.)-500 (T)35 (ugwell P)111 (, Pincus )18 (T)74 (, )37 (Y)100 (ocum D, et al. Combination therapy with)]TJ
2.25 -1.25 Td
[(cyclosporine and methotrexate in severe rheumatoid arthritis. )18 (The)]TJ
T*
(Methotrexate-Cyclosporine Combination Study Group. N Engl J)Tj
T*
(Med 1995;333:137-41.)Tj
-2.25 -1.25 Td
[(231.)-500 (Maini R, St. Clair EW)92 (, Breedveld F)80 (, et al for the )55 (A)111 (TTRACT)-257 (Study)]TJ
-0.00011 Tc 2.25 -1.25 Td
(Group. Infliximab \(chimeric anti-tumour necrosis factor a)Tj
0 Tc T*
(monoclonal antibody\) versus placebo in rheumatoid arthritis patients)Tj
T*
(receiving concomitant methotrexate: a randomised phase III trial.)Tj
T*
(Lancet 1999;354:1932-9.)Tj
30.75 30 Td
[(232.)-500 (Mottonen )18 (T)74 (, Hannonen P)111 (, Leirisalo-Repo M, et al. Comparison of)]TJ
2.25 -1.25 Td
(combination therapy with single-drug therapy in early rheumatoid)Tj
-0.00011 Tc T*
(arthritis: a randomised trial. FIN-RACo trial group. Lancet)Tj
0 Tc 0 Tw T*
(1999;353:1568-73.)Tj
-0.00011 Tc 0.02499 Tw -2.25 -1.25 Td
[(233.)-500 (O\222Dell JR, Haire CE, Erickson N, et al. )18 (T)35 (reatment of rheumatoid)]TJ
0 Tc 2.25 -1.25 Td
(arthritis with methotrexate alone, sulfasalazine and)Tj
T*
(hydroxychloroquine, or a combination of all three medications. )Tj
T*
(N Engl J Med 1996;334:1287-91.)Tj
-2.25 -1.25 Td
[(234.)-500 (Galindo-Rodriguez G, )55 (A)74 (vina-Zubieta JA, Fitzgerald )55 (A, et al.)]TJ
2.25 -1.25 Td
[(V)111 (ariations and trends in the prescription of initial 2nd line therapy)]TJ
T*
(for patients with RA. J Rheumatol 1997;24:633-8.)Tj
-0.00011 Tc -2.25 -1.25 Td
[(235.)-500 (Edmonds JP)111 (, Scott DC, Furst DE, Brooks P)111 (, Paulus HE.)]TJ
0 Tc 2.25 -1.25 Td
[(Antirheumatic drugs: a proposed new classification. )55 (Arthritis Rheum)]TJ
0 Tw T*
(1993;36:336-9.)Tj
-0.00011 Tc 0.02499 Tw -2.25 -1.25 Td
[(236.)-500 (Boers M, )18 (V)111 (erhoeven )55 (AC, Markusse HM, et al. Randomised)]TJ
0 Tc 2.25 -1.25 Td
(comparison of combined step-down prednisolone, methotrexate and)Tj
T*
(sulphasalazine with sulphasalazine in early rheumatoid arthritis.)Tj
T*
(Lancet 1997;350:309-18.)Tj
-0.00011 Tc -2.25 -1.25 Td
[(237.)-500 (Pincus )18 (T)74 (, O\222Dell JR, Kremer JM. Combination therapy with)]TJ
0 Tc 2.25 -1.25 Td
(multiple disease-modifying antirheumatic drugs in rheumatoid)Tj
T*
[(arthritis: a preventive strategy)65 (. )55 (Ann Intern Med 1999;131:768-74.)]TJ
-0.00011 Tc -2.25 -1.25 Td
[(238.)-500 (O\222Dell JR, Haire C, Erikson N, et al. Ef)18 (ficacy of triple DMARD)]TJ
0 Tc 2.25 -1.25 Td
[(therapy in patients with RA)-220 (with suboptimal response to)]TJ
T*
(methotrexate. J Rheumatol 1996;23 Suppl 44:72-4.)Tj
/TT1 1 Tf
11.04516 -56.06811 Td
(The Journal of Rheumatology 2001; 28:6)Tj
0 Tw -46.2952 -0.0313 Td
(1452)Tj
ET
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
54 54 m
558 54 l
S
Q
Q
q
1 0 0 1 0 3 cm
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
101.25 56.28 407.5 -10.83 re
f*
Q
Q
q
1 0 0 1 0 3 cm
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
0.5 w
101.25 56.28 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
114 0 obj
<>
endobj
440 0 obj
<>
endobj
95 0 obj
<>
endobj
90 0 obj
<>
endobj
92 0 obj
<>
endobj
109 0 obj
<>stream
HVpTι&"ApDL7$<\ (c